guidelines:
  1: Brescia_COVID_Respiratory_Severity_Scale_BCRSS_Algorithm_guideline.v1
test_cases:
- id: Level 0
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 0|local::at0046|No|
      gt0008|Respiratory rate >22: 0|local::at0048|No|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 0|local::at0050|No|
      gt0010|Repeat CXR is significantly worsening: 0|local::at0052|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 0
      gt0021|Medications: Lopinavir/ Ritonavir.
      gt0019|Level: 0
      gt0020|Management: Keep patient monitored with SpO2 (pulse oximetry) and clinical evaluation.
- id: Level 1
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 0|local::at0048|No|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 0|local::at0050|No|
      gt0010|Repeat CXR is significantly worsening: 0|local::at0052|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 1
      gt0021|Medications: Lopinavir/ Ritonavir.
      gt0019|Level: 1
      gt0020|Management: Provide supplemental O2. Keep patient monitored with SpO2 (pulse oximetry) and clinical evaluation.
- id: Level  2
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 0|local::at0050|No|
      gt0010|Repeat CXR is significantly worsening: 0|local::at0052|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 2
      gt0021|Medications: Lopinavir/ritonavir. Consider dexamethasone
      gt0019|Level: 2
      gt0020|Management: Perform CXR and ABG. Provide supplemental O2. Keep patient monitored with pulse oximetry and clinical evaluation.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Level  3
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 0|local::at0052|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 3
      gt0021|Medications: Lopinavir/ritonavir. Consider dexamethasone and consider starting Tocilizumab.
      gt0019|Level: 3
      gt0020|Management: Trial of non-invasive ventilation (CPAP/BiPAP) or high-flow nasal canula (HFNC) recommended. If above clinical criteria worsening or patient clinically worsening despite this trial, intubation recommended. Otherwise, perform CXR every 2 days and ABG twice a day.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Re-select number of criteria
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0033|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Lopinavir/ritonavir. Consider dexamethasone and consider starting Tocilizumab.
      gt0019|Level: 3
      gt0020|Management: Trial of non-invasive ventilation (CPAP/BiPAP) or high-flow nasal canula (HFNC) recommended. If above clinical criteria worsening or patient clinically worsening despite this trial, intubation recommended. Otherwise, perform CXR every 2 days and ABG twice a day.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
      gt0036|Comment: Re-select number of criteria present and follow management.
- id: Level 4
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0032|Yes|
      gt0012|Is the intubated patient on CMV?: local::at0036|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Remdesivir (if not available, lopinavir/ritonavir) PLUS considering dexamethasone and tocilizumab.
      gt0019|Level: 4
      gt0020|Management: Follow ICU protocols; use local ventilator weaning protocol.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Level 5
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0032|Yes|
      gt0012|Is the intubated patient on CMV?: local::at0035|Yes|
      gt0013|PaO2/FiO2 <150 mmHg: local::at0039|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Remdesivir (if not available, lopinavir/ritonavir) PLUS considering dexamethasone and tocilizumab.
      gt0019|Level: 5
      gt0020|Management: Try to minimize sedation (RASS -1 to 0). Perform SBT daily.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Level 6
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0032|Yes|
      gt0012|Is the intubated patient on CMV?: local::at0035|Yes|
      gt0013|PaO2/FiO2 <150 mmHg: local::at0038|Yes|
      gt0014|Patient on neuromuscular blockade (NMBA): local::at0042|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Remdesivir (if not available, lopinavir/ritonavir) PLUS considering dexamethasone and tocilizumab.
      gt0019|Level: 6
      gt0020|Management: Try to minimize sedation (RASS -1 to 0).
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Level 7
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0032|Yes|
      gt0012|Is the intubated patient on CMV?: local::at0035|Yes|
      gt0013|PaO2/FiO2 <150 mmHg: local::at0038|Yes|
      gt0014|Patient on neuromuscular blockade (NMBA): local::at0041|Yes|
      gt0015|Patient prone or on ECMO: local::at0045|No|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Remdesivir (if not available, lopinavir/ritonavir) PLUS considering dexamethasone and tocilizumab.
      gt0019|Level: 7
      gt0020|Management: Perform best PEEP and Compliance calculation. Try to suspend NMBA. Optimize volume status.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
- id: Level 8
  input:
    1:
      gt0003|Patient has COVID-19 pneumonia: local::at0005|Yes|
      gt0004|COVID-19 symptoms for ≥7 days: local::at0010|No|
      gt0005|Patient is PCR positive: local::at0012|Yes|
      gt0006|High suspicion for COVID-19/PCR pending: local::at0016|No|
      gt0007|Patient wheezing OR unable to speak in full sentences while at rest/with minimal effort: 1|local::at0047|Yes|
      gt0008|Respiratory rate >22: 1|local::at0049|Yes|
      gt0009|PaO2 <65 mmHg or SpO2 <90%: 1|local::at0051|Yes|
      gt0010|Repeat CXR is significantly worsening: 1|local::at0053|Yes|
      gt0011|Does patient still have >2 criteria despite NIV/HFNC?: local::at0032|Yes|
      gt0012|Is the intubated patient on CMV?: local::at0035|Yes|
      gt0013|PaO2/FiO2 <150 mmHg: local::at0038|Yes|
      gt0014|Patient on neuromuscular blockade (NMBA): local::at0041|Yes|
      gt0015|Patient prone or on ECMO: local::at0044|Yes|
  expected_output:
    1:
      gt0017|Tesing criteria score: 4
      gt0021|Medications: Remdesivir (if not available, lopinavir/ritonavir) PLUS considering dexamethasone and tocilizumab.
      gt0019|Level: 8
      gt0020|Management: Extreme level of medical complexity given failing other management options; defer to clinician expertise.
      gt0023|Inclusion criteria for tocilizumab: First, end of the initial phase of high viral load of COVID-19 (e.g. apyretic from >72h and/or elapsed ≥7 days after the onset of symptoms). Second, worsening of respiratory exchanges, such as to require non-invasive or invasive support from ventilation (Level ≥3). Third, High levels of IL-6 (>40 pg/mL); alternatively high levels of d-dimer, CRP, ferritin, and/or fibrinogen progressively increasing.
      gt0022|Medication consideration: local::at0007|Consider age/comorbidities, cognitive decline.|
